The drug overdose crisis in the United States has evolved through several distinct phases, each more deadly than the last. The current phase, often called the “fourth wave,” is defined by fentanyl combining with stimulants like methamphetamine and cocaine, either through intentional polysubstance use or, far more commonly, through contamination of the drug supply. For people who use methamphetamine today, this means that every use carries a risk that did not exist in prior decades: unknowing exposure to one of the most potent opioids ever encountered in the illicit market.
According to NIDA, nearly 70 percent of stimulant-involved overdose deaths in 2023 also involved illicitly manufactured fentanyl (IMF). That figure is not about people who chose to combine drugs. It reflects a drug supply in which fentanyl has become a near-universal contaminant. A person who buys and uses only methamphetamine today has a substantial probability of also being exposed to fentanyl through that same supply chain, without knowing it, without wanting it, and without any of the physiological tolerance to opioids that would offer any protection.
This article explains how the meth-fentanyl combination became so prevalent, why the two drugs are particularly dangerous together, what the mortality data show, and what people who use meth, and the people who care about them, need to know to reduce the risk of a fatal outcome. It also addresses the treatment implications: what it means to treat someone with both methamphetamine use disorder and opioid exposure, and why naloxone has become an essential tool even for people who primarily use stimulants.
How Fentanyl Got Into the Meth Supply
Fentanyl is a synthetic opioid approximately 100 times more potent than morphine. It was originally developed for medical use in pain management, but illicitly manufactured fentanyl (IMF) has flooded the U.S. drug supply since around 2013, first appearing predominantly in the heroin supply and then expanding into virtually every corner of the illicit market.
The presence of fentanyl in methamphetamine is not primarily a story about people who want both drugs. It is primarily a story about supply chain contamination and, in some cases, deliberate adulteration. Fentanyl is extraordinarily cheap (the DEA has estimated a cost of just a few cents per dose at production-level pricing), and its extreme potency means that a tiny amount dramatically intensifies any drug it is added to. Some distributors add it intentionally to increase the perceived potency and addictive pull of their product. Others may handle fentanyl and meth in the same facilities or with the same equipment, resulting in cross-contamination without intent.
As documented by the CDC, fentanyl is colorless, odorless, and tasteless in the quantities involved in drug supply contamination. There is no way to detect fentanyl by looking at, smelling, or tasting meth. The only reliable detection method is fentanyl test strips, which can indicate whether fentanyl is present in a sample, though they cannot quantify the amount or guarantee the tested portion is representative of the entire batch.
Intentional vs. Unintentional Co-Use
Not everyone who experiences a meth-fentanyl combination overdose is exposed unknowingly. Some people deliberately combine opioids and stimulants, a practice sometimes called “goofballing” (specifically with meth and heroin or fentanyl) or speedballing (with cocaine and opioids). The pharmacological logic is that the stimulant counteracts the sedative effects of the opioid, allowing users to use more opioid without falling asleep. The cardiovascular consequences are severe.
However, the peer-reviewed research literature on fentanyl contamination of stimulant supplies makes clear that inadvertent exposure is the primary driver of the surge in meth-fentanyl overdose deaths. A 2023 study published in Drug and Alcohol Dependence (PMC), which analyzed samples from community-based drug checking services across 25 U.S. states, found fentanyl in a significant share of methamphetamine samples submitted by people who reported expecting pure stimulants. Many people using meth have no opioid tolerance, making even a small dose of fentanyl potentially lethal.
The geographic pattern adds context. Researchers cited by NPR have noted that in the South and West, fentanyl is more likely to appear in methamphetamine than in cocaine, while in the Northeast, contamination is more common in the cocaine supply, reflecting regional drug supply patterns and trafficking route differences. Both represent the same underlying dynamic: fentanyl has become so pervasive in the illicit drug market that no supply is reliably clean.
Why Meth and Fentanyl Are Particularly Dangerous Together
The combination of a stimulant and an opioid creates cardiovascular and respiratory stresses that compound in dangerous ways. Methamphetamine increases heart rate, blood pressure, body temperature, and the demand for oxygen. Fentanyl simultaneously decreases the respiratory drive, meaning the body’s ability and impulse to breathe. The result is a body that requires more oxygen while receiving less of it.
Stimulants may also mask the sedation that typically signals opioid overdose. A person who has used meth alongside fentanyl may remain awake and appear alert even as respiratory function is compromised, potentially delaying the recognition that an overdose is occurring. Bystanders, and the person themselves, may not recognize the danger signs until the situation is critical.
The CDC SUDORS data (2021–2024) found that people who died from meth-and-opioid combination overdoses were more likely to be younger, more likely to have a history of opioid use, and more likely to have received prior SUD treatment than those who died from meth alone, suggesting that this group includes people actively engaged with the treatment system who nonetheless could not avoid the contaminated supply.
The Mortality Data
The scale of meth-fentanyl co-involvement in overdose deaths is staggering. According to NIDA’s overdose death rate data, deaths involving psychostimulants (primarily meth) rose from approximately 5,700 in 2015 to 34,855 in 2023. The primary driver of this increase is opioid co-involvement, and within opioid co-involvement, illicitly manufactured fentanyl is the dominant factor. The percentage of overdose deaths involving the combination of fentanyl and stimulants increased approximately 50-fold between 2010 and 2021, a faster escalation than any prior drug mortality trend in U.S. history.
The CDC MMWR report on stimulant-involved overdose deaths (August 2025) documented that of 309,274 overdose deaths analyzed from January 2021 through June 2024, 59 percent involved any stimulant, 31.2 percent specifically involved methamphetamine, and 68.8 percent of methamphetamine-involved deaths co-involved opioids. Among the co-opioid deaths, fentanyl was the predominant opioid present.
Provisional 2024 data show an overall decline in overdose deaths, with psychostimulant-involved deaths also declining in line with the broader trend, largely driven by reduced fentanyl supply rather than reduced meth use or increased treatment access. Deaths involving stimulants without fentanyl co-involvement continued on an upward trajectory through 2024, meaning the meth crisis itself has not resolved.
Naloxone: Why It Matters for Meth Users
Naloxone (brand names Narcan, Kloxxado, RiVive, and others) is a medication that rapidly reverses opioid overdose by blocking opioid receptors in the brain. It is effective, fast-acting, and safe; it causes no harm if administered to someone who has not taken opioids. Because the vast majority of meth-involved overdose deaths now co-involve opioids, naloxone is recommended for people who use methamphetamine, even if they do not believe they are using opioids.
The logic is straightforward: given that nearly 69 percent of meth-involved overdose deaths involve fentanyl, and given that fentanyl contamination of the meth supply is undetectable by sight, smell, or taste, the most rational harm reduction strategy is to ensure naloxone is available whenever meth is being used. If fentanyl is present and causes respiratory depression, naloxone can reverse it. If fentanyl is not present, naloxone has no significant effect.
Naloxone is available without a prescription at most pharmacies across the United States. As noted by the CDC, it is increasingly available in naloxone vending machines, community distribution programs, and emergency department discharge programs. People who use meth, their family members, and anyone in close proximity to someone who uses meth should know how to administer naloxone and have it available.
Fentanyl Test Strips: A Detection Tool
Fentanyl test strips (FTS) can detect the presence of fentanyl in a drug sample before use. They were originally designed for testing urine and have been adapted for harm reduction use by dissolving a small amount of the drug in water and dipping the strip. A positive result indicates fentanyl is present; a negative result reduces but does not eliminate risk, since the tested portion may not represent the entire batch, and the strips may not detect all fentanyl analogs.
Despite their limitations, fentanyl test strips are among the most practical tools available for reducing fentanyl-related overdose risk. Several states have moved to legalize or decriminalize their use and distribution. They had previously been classified as drug paraphernalia in some jurisdictions. Federal funding has expanded support for their distribution through harm reduction programs.
For people who use meth, using a test strip before use represents a practical step that can literally be the difference between life and death. Harm reduction programs, local health departments, and many pharmacies can provide fentanyl test strips and information on how to use them correctly.
Treatment Implications: Addressing Both Substances
The meth-fentanyl combination creates specific challenges for the treatment system. Someone presenting with both methamphetamine use disorder and fentanyl exposure, whether through intentional polysubstance use or supply contamination, may need care that addresses both substances simultaneously.
For people with both stimulant and opioid use disorders, treatment is complex. FDA-approved medications for opioid use disorder (methadone, buprenorphine, and naltrexone) are available and effective for the opioid component. There is currently no FDA-approved medication for methamphetamine use disorder, so the stimulant component relies on behavioral treatment: CBT, contingency management, and the Matrix Model. Integrated care that addresses both simultaneously produces better outcomes than sequential or siloed treatment (when different health conditions are treated separately by different providers who do not communicate or coordinate with each other; leads to worse outcomes when multiple conditions need to be addressed together).
Treatment programs working with populations that use meth should screen for opioid co-use or co-exposure, and should be prepared to initiate medication-assisted treatment for opioid use disorder alongside behavioral treatment for meth. Programs that treat meth without screening for opioid involvement may miss a significant proportion of the current treatment-seeking population’s actual clinical needs.
When I worked with people coming off stimulants, the first couple of days looked different from opioid or alcohol withdrawal. With opioids and alcohol, you are watching a lot of physical symptoms. With meth, crack, and cocaine, a lot of what you are dealing with is mental and emotional, and a big part of that comes from how little the person has slept. Many of them had been on long benders and were so sleep-deprived they were almost in a psychosis. So early on, the priority was letting them sleep while making sure they were safe, eating, and getting fluids back in. Sleep was not just rest in those cases. It was one of the main things the body and mind needed to start coming back.
What has changed since my years on the floor is the supply itself. Someone using meth today can be exposed to fentanyl without knowing it and without any opioid tolerance to protect them, and that specific danger is newer than most of the cases I worked with directly. But where I stand on it is simple. Keeping someone alive matters. If naloxone is the reason a person is still here to get another chance, that is worth it. Staying alive is not the same thing as recovering, though. For me, the point of keeping someone alive is so they can get into treatment and deal with what is underneath the use. That is where the real work happens, and it is the part I spent years doing.
Conclusion
Fentanyl has transformed the risk profile of methamphetamine use. Nearly 70% of methamphetamine-involved overdose deaths co-involve opioids, primarily through intentional co-use of separate stimulant and opioid products rather than supply contamination. This makes naloxone and fentanyl test strips essential tools for anyone in contact with the current meth supply, not just people who intentionally use opioids. Treatment programs, harm reduction services, and public health systems need to integrate a response to the meth-fentanyl overlap that addresses both substances and the lethal risk created by their convergence.